Loading...
CAR-T Advancements Will Expand Global Cancer Therapy Access
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
25 Aug 25
Updated
25 Aug 25
AnalystHighTarget's Fair Value
US$94.00
62.7% undervalued intrinsic discount25 Aug
US$35.08
1Y
-38.5%7D
-4.0%1Y
-38.5%7D
-4.0%